Biotechnology company Enveric Biosciences has selected EB-003 as its lead drug candidate from its EVM301 series for difficult-to-treat mental health disorders. EB-003 was selected by the company based on data assessments indicating its potential to offer a first-in-class approach to treat these disorders. It works by boosting neuroplasticity without causing hallucinations.
